CLINICAL CHARACTERISTICS AND ¹⁸FDG PET/CT IMAGING IN DIFFERENTATEDTHYROID CARCINOMA PATIENTS WITH NEGATIVE ¹³¹I WHOLE-BODY SCAN AND ELEVATED SERUM THYROGLOBULIN
Main Article Content
Abstract
Differentiated thyroid carcinoma (DTC) represents about 1 – 1.5% of all malignant tumors. Post-surgical total thyroidectomy and 131 I therapy patients have a 10-year survival rate of 85 – 90%. However, DTC patients have a less favorable prognosis if radioiodine - negative tumor tissues, especially in distant metastases, is present. Several studies showed that 18FDG PET/CT can improve the diagnostic work-up of these patients with negative radioiodine scintigraphy but metastatic spread associated with an increase of serum thyroglobulin.
Article Details
Keywords
¹⁸FDG PET/CT, ¹³¹I
References
[1] Domonique Delbeke, R. Edward Coleman et al. (2006). Proceduce guideline for tumor imaging with 18-F FDG PET/CT 1*. SNM 2006.
[2] James W. Fletcher et al. Recommedation on the use of 18-F FDG PET in Oncology. J Nucl Med 2008; 49: 480 – 508.
[3] HolgerPalmedo, Jan Bucerius, Alexius Joe et al. (2006). Integrated PET/CT in differentiated thyroid cancer: Diagnostic accuracy and impact on patients management. J Nucl Med; 47: 616 – 624.
[4] Hui Wang, Hong Liang Fu, Jia Ning Li et al. (2008). Comparison of whole-body 18F-FDG SPECT and posttherapeutic I-131 scintigraphy in the detection of metastatic thyroid cancer. Clinical Imaging 32: 32 – 37.
[5] Mi-Yeon Choi, June-Key Chung, Ho-Yeong Lee et al. (2006). The clinical impact of 18F – FDG PET in papillary thyroid carcinoma with a negative I-131 whole body scan: a single-center study of 108 patients. Annals of Nuclear Medicine 20 (8): 547 – 552.
[6] Peter Lind, Susanne Kohlfrst (2006). Respective roles of thyroglobulin, radioiodine imaging and positron emission tomography in the assessment of thyroid cancer. Semi Nucl Med 36: 194 – 205.
[7] Steven M. Larson, Richard Robbins (2002). Positron Emission Tomography in thyroid cancer management. Seminar in Roentgenology, 37 (2): 169 – 174.
[8] Ha T.T. Phan, Pieter L. Jager et al. (2008). Comparison of C-11 methionine PET and 18F- Fluorodeoxyglucose PET in differentiated thyroid cancer. Nuclear Medicine Communication, 29: 711 – 716.
[2] James W. Fletcher et al. Recommedation on the use of 18-F FDG PET in Oncology. J Nucl Med 2008; 49: 480 – 508.
[3] HolgerPalmedo, Jan Bucerius, Alexius Joe et al. (2006). Integrated PET/CT in differentiated thyroid cancer: Diagnostic accuracy and impact on patients management. J Nucl Med; 47: 616 – 624.
[4] Hui Wang, Hong Liang Fu, Jia Ning Li et al. (2008). Comparison of whole-body 18F-FDG SPECT and posttherapeutic I-131 scintigraphy in the detection of metastatic thyroid cancer. Clinical Imaging 32: 32 – 37.
[5] Mi-Yeon Choi, June-Key Chung, Ho-Yeong Lee et al. (2006). The clinical impact of 18F – FDG PET in papillary thyroid carcinoma with a negative I-131 whole body scan: a single-center study of 108 patients. Annals of Nuclear Medicine 20 (8): 547 – 552.
[6] Peter Lind, Susanne Kohlfrst (2006). Respective roles of thyroglobulin, radioiodine imaging and positron emission tomography in the assessment of thyroid cancer. Semi Nucl Med 36: 194 – 205.
[7] Steven M. Larson, Richard Robbins (2002). Positron Emission Tomography in thyroid cancer management. Seminar in Roentgenology, 37 (2): 169 – 174.
[8] Ha T.T. Phan, Pieter L. Jager et al. (2008). Comparison of C-11 methionine PET and 18F- Fluorodeoxyglucose PET in differentiated thyroid cancer. Nuclear Medicine Communication, 29: 711 – 716.